Concepedia

Michael D. Farwell

MD

25

Publications

2.3K

Citations

17

H-Index

2012

Active since

Affiliations

University of Pennsylvania(Current)

Children's Hospital of Philadelphia

Parker Institute for Cancer Immunotherapy

Abramson Cancer Center

Merck & Co., Inc., Rahway, NJ, USA (United States)

Michael D. Farwell is an author at University of Pennsylvania specializing in medicine, oncology, and cancer therapeutics.

Top concepts

MedicineOncologyImmunologyImmunotherapyCancer TherapyCell BiologyTumor ImmunityRadiation OncologyTumor MicroenvironmentUrology

Publications per year

2012–2024

25

Publications

25

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

Alexander C. Huang, Robert Orlowski, Xiaowei Xu et al. · Nature Medicine · 2019 · 683 citations

Neoadjuvant Pd-1 Blockade, Surgical Oncology, Medicine +11

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Vivek Narayan, Julie S. Barber-Rotenberg, In-Young Jung et al. · Nature Medicine · 2022 · 455 citations · Full text

Urology, Cancer Immunosurveillance, Genitourinary Cancer +6

First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Neeta Pandit‐Taskar, Michael A. Postow, Matthew D. Hellmann et al. · Journal of Nuclear Medicine · 2019 · 249 citations · Full text

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer

Mehran Makvandi, Austin R. Pantel, Lauren E. Schwartz et al. · Journal of Clinical Investigation · 2018 · 131 citations · Full text

CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody

Michael D. Farwell, Raymond F. Gamache, Hasan Babazada et al. · Journal of Nuclear Medicine · 2021 · 113 citations · Full text

Rows per page

1–5 of 25